Display options
Cite
Guariglia R, Martorelli MC, Lerose R, et al. Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients. Biologics. 2016;10:1-8doi: 10.2147/BTT.S58597.
Guariglia, R., Martorelli, M. C., Lerose, R., Telesca, D., Milella, M. R., & Musto, P. (2016). Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients. Biologics : targets & therapy, 101-8. https://doi.org/10.2147/BTT.S58597
Guariglia, Roberto, et al. "Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients." Biologics : targets & therapy vol. 10 (2016): 1-8. doi: https://doi.org/10.2147/BTT.S58597
Guariglia R, Martorelli MC, Lerose R, Telesca D, Milella MR, Musto P. Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients. Biologics. 2016 Jan 22;10:1-8. doi: 10.2147/BTT.S58597. eCollection 2016. PMID: 26858523; PMCID: PMC4730998.
Copy Download .nbib Format: NLM
Share it on

Biologics. 2016 Jan 22;10:1-8. doi: 10.2147/BTT.S58597. eCollection 2016.

Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients.

Biologics : targets & therapy

Roberto Guariglia, Maria Carmen Martorelli, Rosa Lerose, Donatella Telesca, Maria Rita Milella, Pellegrino Musto

Affiliations

  1. Unit of Hematology and Stem Cell Transplantation, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture, Potenza, Italy.
  2. Pharmacy Service, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture, Potenza, Italy.
  3. Scientific Direction, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture, Potenza, Italy.

PMID: 26858523 PMCID: PMC4730998 DOI: 10.2147/BTT.S58597

Abstract

Neutropenia and febrile neutropenia (FN) are frequent and potentially fatal toxicities of myelosuppressive anticancer treatments. The introduction of granulocyte colony-stimulating factors (G-CSFs) in clinical practice has remarkably reduced the duration and severity of neutropenia, as well as the incidence of FN, thus allowing the administration of chemotherapeutic agents at the optimal dose and time with lower risk. The current scenario of G-CSFs in Europe includes filgrastim, lenograstim, some G-CSF biosimilars, and pegfilgrastim. Recently, a novel long-acting G-CSF, lipegfilgrastim, became available. Lipegfilgrastim is a glycopegylated G-CSF, alternative to pegfilgrastim, and has shown in randomized trials, to be equivalent to pegfilgrastim in reducing the incidence of severe neutropenia and FN in patients with breast cancer receiving chemotherapy, with a similar safety profile. Furthermore, lipegfilgrastim was more effective than the placebo in reducing the incidence of severe neutropenia, its duration, and time to absolute neutrophil count recovery, in patients with non-small cell lung cancer receiving myelosuppressive therapy. Although the number of studies currently published is still limited, lipegfilgrastim seems to be a promising drug in the management of chemotherapy-induced neutropenia.

Keywords: G-CSF; febrile neutropenia; granulocyte colony-stimulating factors; lipegfilgrastim; neutropenia; pegfilgrastim

References

  1. J BUON. 2009 Apr-Jun;14(2):203-9 - PubMed
  2. Expert Rev Clin Pharmacol. 2015 Jan;8(1):15-24 - PubMed
  3. Ann Oncol. 2005 Sep;16(9):1413-24 - PubMed
  4. Expert Opin Investig Drugs. 2014 Jan;23(1):21-35 - PubMed
  5. Eur J Cancer. 1993;29A(3):319-24 - PubMed
  6. Cancer. 2006 May 15;106(10):2258-66 - PubMed
  7. Nat Rev Drug Discov. 2014 Feb;13(2):99-100 - PubMed
  8. Anticancer Res. 1996 Jul-Aug;16(4A):1781-5 - PubMed
  9. Eur J Cancer. 1994;30A Suppl 3:S12-4 - PubMed
  10. Ann Oncol. 2002 Oct;13(10):1519-30 - PubMed
  11. Int J Clin Pharmacol Ther. 2011 Aug;49(8):510-8 - PubMed
  12. N Engl J Med. 2010 Dec 2;363(23):2200-10 - PubMed
  13. Ann Oncol. 2010 May;21 Suppl 5:v252-6 - PubMed
  14. Oncol Res Treat. 2015;38(5):221-9 - PubMed
  15. Blood. 1997 Dec 15;90(12):4710-8 - PubMed
  16. Cancer. 2000 Feb 15;88(4):796-803 - PubMed
  17. Cancer. 2011 May 1;117(9):1917-27 - PubMed
  18. Breast Cancer Res Treat. 2014 Nov;148(1):107-16 - PubMed
  19. Expert Opin Biol Ther. 2008 Jul;8(7):993-1001 - PubMed
  20. Bone Marrow Transplant. 2015 Apr;50(4):523-30 - PubMed
  21. Ann Oncol. 2009 Jan;20(1):34-40 - PubMed
  22. Springerplus. 2015 Jul 03;4:316 - PubMed
  23. Clin Cancer Res. 2001 Jul;7(7):2085-90 - PubMed
  24. Ann Oncol. 2003 Jan;14(1):29-35 - PubMed
  25. Breast Cancer Res Treat. 2009 Apr;114(3):479-84 - PubMed
  26. Eur J Cancer. 1994;30A Suppl 3:S2-6 - PubMed
  27. Ann Oncol. 2009 Mar;20(3):513-9 - PubMed
  28. Curr Med Res Opin. 2014 Dec;30(12):2523-33 - PubMed
  29. N Engl J Med. 1991 Jul 18;325(3):164-70 - PubMed
  30. J Natl Compr Canc Netw. 2009 Jan;7(1):99-108 - PubMed
  31. Leuk Res. 2007 Nov;31(11):1487-93 - PubMed
  32. Haematologica. 2005 Dec;90(12):1665-71 - PubMed
  33. Cancer. 2007 Oct 1;110(7):1611-20 - PubMed
  34. Haematologica. 2006 Apr;91(4):496-502 - PubMed
  35. BMC Cancer. 2013 Aug 14;13:386 - PubMed
  36. Eur J Cancer. 2011 Jan;47(1):8-32 - PubMed
  37. Ann Hematol. 2008 Apr;87(4):277-83 - PubMed
  38. Pharmazie. 2014 May;69(5):323-6 - PubMed
  39. Support Care Cancer. 2016 Jan;24(1):267-73 - PubMed
  40. J Clin Pharmacol. 2016 Feb;56(2):186-94 - PubMed
  41. Support Care Cancer. 2016 Jan;24(1):395-400 - PubMed
  42. Oncologist. 2005 Jun-Jul;10(6):427-37 - PubMed
  43. Infection. 2014 Feb;42(1):5-13 - PubMed
  44. Support Care Cancer. 2015 Feb;23(2):525-45 - PubMed
  45. N Engl J Med. 2002 Jan 24;346(4):235-42 - PubMed
  46. Leuk Lymphoma. 2003 Oct;44(10):1691-6 - PubMed
  47. Methods Mol Biol. 2012;904:37-47 - PubMed
  48. Cancer Control. 2002 May-Jun;9(3):203-11 - PubMed
  49. J Clin Oncol. 2015 Oct 1;33(28):3199-212 - PubMed
  50. Support Cancer Ther. 2003 Oct 1;1(1):23-35 - PubMed
  51. Cancer. 2004 Jan 15;100(2):228-37 - PubMed

Publication Types